摘要
Brain ischemia is the second leading cause of death and the third leading cause of disability in the world.Systemic delivery of microRNA,a class of molecules that regulate the expression of cellular proteins associated with angiogenesis,cell growth,proliferation and differentiation,holds great promise for the treatment of brain ischemia.However,their therapeutic efficacy has been hampered by poor delivery efficiency of microRNA.We report herein a platform technology based on microRNA nanocapsules,which enables their effective delivery to the disease sites in the brain.Exemplified by microRNA-21,intravenous injection of the nanocapsules into a rat model of cerebral ischemia could effectively ameliorate the infarct volume,neurological deficit and histopathological severity.
基金
supported by the National Key Research and Development Program of China(No.2019YFA0903801)
the National Natural Science Foundation of China(Nos.52073015,51773151,52003021,and 81671169)
Tianjin Municipal Health Bureau(No.2010KY11)
Postdoctoral Science Foundation of China(No.2015M580212)
Fundamental Research Funds for the Central Universities(No.ZY2006).
